Two Sigma Securities’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$201K Buy
+1,065
New +$186K 0.02% 1052
2024
Q3
Sell
-3,848
Closed -$422K 3245
2024
Q2
$411K Buy
+3,848
New +$423K 0.01% 1713
2024
Q1
Sell
-1,717
Closed -$211K 3285
2023
Q4
$211K Sell
1,717
-972
-36% -$121K ﹤0.01% 2355
2023
Q3
$348K Buy
2,689
+459
+21% +$61.2K ﹤0.01% 1822
2023
Q2
$276K Buy
+2,230
New +$300K ﹤0.01% 1942
2022
Q4
Sell
-2,077
Closed -$277K 2921
2022
Q3
$277K Buy
2,077
+619
+42% +$94.1K 0.01% 1652
2022
Q2
$227K Sell
1,458
-643
-31% -$99K 0.01% 1541
2022
Q1
$327K Buy
2,101
+197
+10% +$28.6K 0.01% 1333
2021
Q4
$243K Buy
1,904
+98
+5% +$12.9K 0.01% 947
2021
Q3
$235K Buy
+1,806
New +$273K 0.01% 1149
2018
Q3
Sell
-1,354
Closed -$233K 2801
2018
Q2
$233K Buy
+1,354
New +$221K ﹤0.01% 2244
2017
Q1
Sell
-2,944
Closed -$321K 1012
2016
Q4
$321K Buy
+2,944
New +$328K 0.11% 241

Other funds holding JAZZ

Two Sigma Securities's JAZZ Position: Q1 2026 in Review

Two Sigma Securities opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 1,065 shares worth $201K. The stake represents 0.02% of the portfolio and ranks #1052 among its holdings. This is a return to the name: Two Sigma Securities previously reported a position in JAZZ as recently as Q2 2024.

Two Sigma Securities first reported a position in JAZZ in Q4 2016 and has held it in 12 quarters since. The position peaked at $411K in Q2 2024. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Two Sigma Securities held 1,065 shares of Jazz Pharmaceuticals worth $201K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Two Sigma Securities position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.02% of Two Sigma Securities's portfolio in Q1 2026, its #1052 holding.
  • Two Sigma Securities first reported a position in Jazz Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
  • Two Sigma Securities's Jazz Pharmaceuticals position peaked at $411K in Q2 2024.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.